8-K Announcements
6Material company update
May 20, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
Mar 25, 2026·SEC
ProMIS Neurosciences, Inc.(PMN)Earnings, Financials & Key Ratios
PMN•NASDAQ
Price updated Jun 11, 2026
AboutProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Show more
- Revenue$0
- EBITDA-$40M-1490.9%
- Net Income-$40M-1529.3%
- EPS (Diluted)-22.61-922.2%
- ROE-521.61%-1999.7%
PMN Key Insights
ProMIS Neurosciences, Inc. (PMN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Profits declining 47.6% over 5 years
- ✗Weak Piotroski F-Score: 0/9
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PMN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PMN Price & Volume
ProMIS Neurosciences, Inc. (PMN) stock price & volume — 10-year historical chart
Loading chart...
PMN Growth Metrics
ProMIS Neurosciences, Inc. (PMN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-4248.84%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2270.85%
Return on Capital
10 Years-579.25%
5 Years-347.23%
3 Years-480.58%
Last Year-519.51%
PMN Recent Earnings
ProMIS Neurosciences, Inc. (PMN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
May 12, 2026EPS
$1.26
Est $1.06
-18.9%
Revenue
—
Q2 2026
May 11, 2026EPS
$1.26
Est $1.06
-18.9%
Revenue
—
Q2 2026
Mar 25, 2026EPS
$4.11
Est $4.66
+11.8%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$6.00
Est $3.75
-60.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $1.26vs $1.06-18.9% | — |
| Q2 2026 | May 11, 2026 | $1.26vs $1.06-18.9% | — |
| Q2 2026 | Mar 25, 2026 | $4.11vs $4.66+11.8% | — |
| Q4 2025 | Nov 12, 2025 | $6.00vs $3.75-60.0% | — |
Based on last 12 quarters of dataView full earnings history →
PMN Peer Comparison
ProMIS Neurosciences, Inc. (PMN) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRTA | 432.44M | 8.26 | -1.82 | -92.84% | -260.92% | -49.88% | 0.05 | |
 ARVN | 457.46M | 7.09 | -5.54 | -0.3% | -247.54% | -44.39% | 0.02 | |
 ACAD | 3.66B | 21.39 | 9.34 | 11.87% | 34.3% | 35.65% | 0.04 | |
 SAVA | 63.77M | 1.32 | -2.54 | -95.77% | ||||
 NRXP | 67.76M | 3.92 | -2.93 | -10.7% | ||||
 BIIB | 29.52B | 199.96 | 22.65 | 1.39% | 13.92% | 7.55% | 0.38 | |
 LLY | 1.1T | 1160.95 | 50.59 | 44.7% | 34.98% | 101.17% | 1.60 | |
 ESPR | 654.91M | 3.15 | -28.64 | 21.31% | -1.77% |
Compare PMN vs Peers
ProMIS Neurosciences, Inc. (PMN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PMN Income Statement
ProMIS Neurosciences, Inc. (PMN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 7.87K | 349 | 1.2K | 1.56K | 8.14K | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | 293.03% | -95.57% | 244.67% | 30.2% | 420.04% | -100% | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 4.74M | 3.18M | 5.85M | 0 | 10.44M | 0 | 0 | 0 |
COGS % of Revenue | - | - | 393953.16% | 203396.1% | 71896.88% | - | - | - | - | - |
Gross Profit | 7.87K▲ 0% | 349▼ 95.6% | -4.73M▼ 1356579.9% | -3.18M▲ 32.8% | -5.84M▼ 83.7% | 0▲ 100.0% | -10.44M▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | 100% | 100% | -393853.16% | -203296.1% | -71796.88% | - | - | - | - | - |
Gross Profit Growth % | 293.03% | -95.57% | -1357575.08% | 32.79% | -83.66% | 100% | - | 100% | - | - |
Operating Expenses | 4.79M | 7.46M | 7.4M | 2.48M | 8.26M | 23.38M | 8.45M | 16.83M | 40.17M | 41.35M |
OpEx % of Revenue | 60866.71% | 2140531.37% | 615429.37% | 158518.08% | 101521.71% | - | - | - | - | - |
Selling, General & Admin | 1.64M | 2.02M | 2.66M | 2.48M | 3.31M | 7.29M | 6.38M | 6.19M | 6.79M | 6.47M |
SG&A % of Revenue | 20832.6% | 580627.08% | 221476.21% | 158532.27% | 40711.26% | - | - | - | - | - |
Research & Development | 3.15M | 5.44M | 4.74M | 3.18M | 4.95M | 16.09M | 7.88M | 10.64M | 33.38M | 34.89M |
R&D % of Revenue | 40034.1% | 1559904.28% | 393953.16% | 203396.1% | 60810.43% | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | -3.18M | 0 | 0 | -5.81M | 0 | 0 | 0 |
Operating Income | -4.78M▲ 0% | -7.46M▼ 56.1% | -12.13M▼ 62.5% | -5.66M▲ 53.3% | -8.25M▼ 45.7% | -23.38M▼ 183.4% | -18.9M▲ 19.2% | -16.83M▲ 11.0% | -40.17M▼ 138.7% | -41.35M▲ 0% |
Operating Margin % | -60766.72% | -2140431.58% | -1009282.53% | -361814.19% | -101363.57% | - | - | - | - | - |
Operating Income Growth % | -86.88% | -56.11% | -62.52% | 53.33% | -45.69% | -183.4% | 19.17% | 10.95% | -138.7% | - |
EBITDA | -4.78M | -7.46M | -12.12M | -5.65M | -8.2M | -23.37M | -18.87M | 2.86M | -39.72M | -41.02M |
EBITDA Margin % | -60699.29% | -2139026.95% | -1008570.38% | -360809.2% | -100800.52% | - | - | - | - | - |
EBITDA Growth % | -87.04% | -56.18% | -62.51% | 53.42% | -45.29% | -184.85% | 19.25% | 115.13% | -1490.9% | -4291.72% |
D&A (Non-Cash Add-back) | 5.31K | 4.9K | 8.56K | 15.73K | 45.83K | 11.22K | 28.04K | 0 | 0 | 0 |
EBIT | -4.78M | -7.46M | -7.4M | -5.66M | -9.37M | -17.78M | -17.84M | 2.86M | -39.72M | -41.02M |
Net Interest Income | -5.65K | 0 | 0 | 0 | -411.55K | -282.06K | -201.39K | -76.78K | 0 | 0 |
Interest Income | 0 | 0 | 0 | 0 | 4.73K | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 5.65K | 0 | 0 | 0 | 416.29K | 282.06K | 201.39K | 76.78K | 0 | 0 |
Other Income/Expense | -5.65K | 0 | 4.74M | 0 | -1.5M | 5.32M | 1.39M | 19.61M | 448.16K | 736.49K |
Pretax Income | -4.79M▲ 0% | -7.46M▼ 55.9% | -7.4M▲ 0.9% | -5.66M▲ 23.4% | -9.24M▼ 63.2% | -18.06M▼ 95.4% | -17.51M▲ 3.1% | 2.78M▲ 115.9% | -39.72M▼ 1529.3% | -40.62M▲ 0% |
Pretax Margin % | -60838.5% | -2140431.58% | -615329.37% | -361814.19% | -113562.83% | - | - | - | - | - |
Income Tax | 5.65K | 0 | 0 | 0 | 415.02K | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.12% | 0% | 0% | 0% | -4.49% | 0% | 0% | 0% | 0% | 0% |
Net Income | -4.79M▲ 0% | -7.46M▼ 55.9% | -7.4M▲ 0.9% | -5.66M▲ 23.4% | -9.66M▼ 70.6% | -18.06M▼ 87.0% | -17.51M▲ 3.1% | 2.78M▲ 115.9% | -39.72M▼ 1529.3% | -40.62M▲ 0% |
Net Margin % | -60838.5% | -2140431.58% | -615329.37% | -361814.19% | -118662.24% | - | - | - | - | - |
Net Income Growth % | -86.24% | -55.93% | 0.92% | 23.44% | -70.56% | -87.03% | 3.08% | 115.87% | -1529.33% | -4248.84% |
Net Income (Continuing) | -4.79M | -7.46M | -7.4M | -5.66M | -9.79M | -18.06M | -17.51M | 2.78M | -39.72M | -40.62M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -35.00▲ 0% | -46.75▼ 33.6% | -32.75▲ 29.9% | -23.25▲ 29.0% | -41.75▼ 79.6% | -42.50▼ 1.8% | -35.50▲ 16.5% | 2.75▲ 107.7% | -22.61▼ 922.2% | -6.22▲ 0% |
EPS Growth % | -53.85% | -33.57% | 29.95% | 29.01% | -79.57% | -1.8% | 16.47% | 107.75% | -922.18% | -2270.85% |
EPS (Basic) | -35.00 | -46.75 | -32.75 | -23.25 | -41.75 | -42.50 | -35.50 | 2.75 | -22.61 | - |
Diluted Shares Outstanding | 137.19K | 159.46K | 173.2K | 190.4K | 231.43K | 300.1K | 491.71K | 1.06M | 1.76B | 6.53M |
Basic Shares Outstanding | 137.19K | 159.46K | 173.2K | 190.4K | 231.42K | 300.1K | 491.71K | 1.04M | 1.76B | 6.53M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
PMN Balance Sheet
ProMIS Neurosciences, Inc. (PMN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 2.11M | 2.91M | 2.03M | 1.24M | 22.4M | 9.35M | 13.62M | 18.91M | 9.18M | 65.61M |
Cash & Short-Term Investments | 1.73M | 2.43M | 1.7M | 1.11M | 21.48M | 8.01M | 12.63M | 13.32M | 6.15M | 63.85M |
Cash Only | 1.69M | 2.39M | 1.66M | 1.03M | 21.43M | 7.96M | 12.6M | 13.29M | 6.12M | 63.81M |
Short-Term Investments | 41.41K | 41.62K | 41.83K | 76.72K | 50.69K | 59.46K | 32.36K | 33.05K | 33.75K | 33.75K |
Accounts Receivable | 2.17K | 1.16K | 0 | 0 | 0 | 0 | 78.64K | 78.03K | 36.52K | 0 |
Days Sales Outstanding | 100.59 | 1.22K | - | - | - | - | - | - | - | - |
Inventory | -36.69K | -40.14K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 43.97K | 53.5K | 74.22K | 78.75K | 768.78K | 571.72K | 228.85K | 47.28K | 70.48K | 1.76M |
Total Non-Current Assets | 63.52K | 56.85K | 48.29K | 144.23K | 40.83K | 28.65K | 0 | 0 | 0 | 1.8M |
Property, Plant & Equipment | 1.89K | 1.89K | 0 | 99.61K | 5.91K | 435 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | 4.17x | 0.18x | - | 0.02x | 1.38x | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 61.64K | 54.96K | 48.29K | 41.62K | 34.92K | 28.21K | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 3K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.8M |
Total Assets | 2.17M▲ 0% | 2.97M▲ 36.6% | 2.07M▼ 30.1% | 1.38M▼ 33.2% | 22.44M▲ 1520.5% | 9.38M▼ 58.2% | 13.62M▲ 45.3% | 18.91M▲ 38.9% | 9.18M▼ 51.4% | 67.41M▲ 0% |
Asset Turnover | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | - | - | - | - | 0.00x |
Asset Growth % | 124.3% | 36.63% | -30.09% | -33.22% | 1520.47% | -58.22% | 45.26% | 38.86% | -51.45% | 904.7% |
Total Current Liabilities | 637.45K | 1.81M | 1.68M | 2.4M | 1.17M | 8.68M | 9.35M | 2.22M | 10.41M | 6.61M |
Accounts Payable | 207.48K | 523K | 465.02K | 557.84K | 517.17K | 4.03M | 7.84M | 1.74M | 2.54M | 1.72M |
Days Payables Outstanding | - | - | 35.84 | 63.97 | 32.26 | - | 274.08 | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 628.79K | 0 | 0 | 0 | 0 | 518.7K | 38.33K | 79.75K | 4.9M |
Current Ratio | 3.31x | 1.61x | 1.21x | 0.52x | 19.07x | 1.08x | 1.46x | 8.52x | 0.88x | 9.92x |
Quick Ratio | 3.36x | 1.63x | 1.21x | 0.52x | 19.07x | 1.08x | 1.46x | 8.52x | 0.88x | 9.92x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 14.11M | 2.52M | 516.19K | 204.85K | 29.18K | 79.38K |
Long-Term Debt | 0 | 0 | 0 | 0 | 4.94M | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 9.17M | 2.52M | 516.19K | 204.85K | 29.18K | 79.38K |
Total Liabilities | 637.45K | 1.81M | 1.68M | 2.4M | 15.28M | 11.2M | 9.87M | 2.42M | 10.44M | 6.69M |
Total Debt | 0 | 0 | 0 | 0 | 4.94M | 0 | 0 | 0 | 0 | 0 |
Net Debt | -1.69M | -2.39M | -1.66M | -1.03M | -16.49M | -7.96M | -12.6M | -13.29M | -6.12M | -63.81M |
Debt / Equity | - | - | - | - | 0.69x | - | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | -4.65x | - | 1.56x |
Interest Coverage | -846.52x | - | - | - | -22.52x | -63.04x | -88.57x | 37.20x | - | - |
Total Equity | 1.53M▲ 0% | 1.16M▼ 24.6% | 398.12K▼ 65.6% | -1.02M▼ 355.2% | 7.16M▲ 804.5% | -1.82M▼ 125.5% | 3.75M▲ 305.7% | 16.49M▲ 339.3% | -1.26M▼ 107.6% | 60.72M▲ 0% |
Equity Growth % | 2108.4% | -24.59% | -65.57% | -355.18% | 804.51% | -125.5% | 305.68% | 339.3% | -107.63% | 542.92% |
Book Value per Share | 11.18 | 7.25 | 2.30 | -5.34 | 30.93 | -6.08 | 7.63 | 15.58 | -0.00 | 9.30 |
Total Shareholders' Equity | 1.53M | 1.16M | 398.12K | -1.02M | 7.16M | -1.82M | 3.75M | 16.49M | -1.26M | 60.72M |
Common Stock | 37.47M | 45.22M | 49.03M | 52.74M | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -48.02M | -58.19M | -65.59M | -71.25M | -78.64M | -108.66M | -93.47M | -90.69M | -130.41M | -138.65M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 4.15M | 6.13M | 8.88M | 9.14M | -237.63K | -264.52K | -371.18K | -371.18K | -371.18K | -371.18K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PMN Cash Flow Statement
ProMIS Neurosciences, Inc. (PMN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -4.53M | -6.35M | -6.09M | -4.35M | -9.44M | -17.03M | -10.84M | -27.18M | -28.12B | -35.47M |
Operating CF Margin % | -57598.6% | -1819727.58% | -506627.7% | -278255.85% | -116017.91% | - | - | - | - | - |
Operating CF Growth % | -139.48% | -40.02% | 4.04% | 28.49% | -116.83% | -80.4% | 36.34% | -150.67% | -103345.22% | -370.09% |
Net Income | -4.79M | -7.46M | -7.4M | -5.66M | -9.4M | -18.06M | -13.21M | 2.78M | -39.72B | -40.62M |
Depreciation & Amortization | 5.31K | 4.9K | 8.56K | 15.73K | 46.46K | 11.22K | 21.16K | 0 | 0 | 0 |
Stock-Based Compensation | 552.11K | 789.21K | 647.39K | 414.51K | 0 | 487.63K | 271.54K | 825.81K | 857.63M | 857.19M |
Deferred Taxes | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -6.79K | 0 | -171.37K | 92.82K | 1.5M | -4.87M | -868.55K | -19.06M | 10.73B | 38.82B |
Working Capital Changes | -295.68K | 324.33K | 822.01K | 784.63K | -1.59M | 5.4M | 2.94M | -11.73M | 14.75M | 4.51M |
Change in Receivables | 0 | 0 | -19.55K | 34.63K | -17.57K | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -303.52K | 331.44K | 0 | 0 | -32.09K | 2.68M | 4.96M | -6.11M | 1.11M | -135.27K |
Cash from Investing | -164 | -152 | -208 | -111.88K | 95.93K | -1.98K | -1.35K | -693 | -702K | -703 |
Capital Expenditures | 0 | 0 | 0 | -108.67K | -6.13K | -1.98K | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | 6943.51% | 75.3% | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 99.7K | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 1 | -208 | -3.21K | 0 | 0 | 0 | 0 | 0 | 701.3K |
Cash from Financing | 5.31M | 6.86M | 5.36M | 3.83M | 25.63M | 6.49M | 17.75M | 27.88M | 20.94B | 91.07M |
Debt Issued (Net) | -89.32K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 5.35M | 5.54M | 0 | 0 | 25.63M | 4.97M | 17.75M | 27.85M | 28.74M | 90.96M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 53.15K | 1.32M | 5.36M | 3.83M | 0 | 1.52M | 3.6K | 28.04K | 20.92B | 103.32K |
Net Change in Cash | 777.5K▲ 0% | 513.87K▼ 33.9% | -727.94K▼ 241.7% | -632.75K▲ 13.1% | 16.17M▲ 2655.4% | -11.07M▼ 168.5% | 6.72M▲ 160.7% | 693.02K▼ 89.7% | -7.17B▼ 1035366.0% | 55.45M▲ 0% |
Free Cash Flow | -4.53M▲ 0% | -6.35M▼ 40.0% | -6.09M▲ 4.0% | -4.46M▲ 26.7% | -9.45M▼ 111.7% | -17.04M▼ 80.3% | -10.84M▲ 36.3% | -27.18M▼ 150.7% | -28.12B▼ 103345.2% | -35.47M▲ 0% |
FCF Margin % | -57598.6% | -1819727.58% | -506627.7% | -285199.36% | -116093.17% | - | - | - | - | - |
FCF Growth % | -139.48% | -40.02% | 4.04% | 26.71% | -111.69% | -80.3% | 36.35% | -150.67% | -103345.22% | -66.25% |
FCF per Share | -33.04 | -39.80 | -35.16 | -23.44 | -40.83 | -56.77 | -22.05 | -25.68 | -16.01 | -5.43 |
FCF Conversion (FCF/Net Income) | 0.95x | 0.85x | 0.82x | 0.77x | 0.98x | 0.94x | 0.62x | -9.78x | 707.94x | 0.87x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 87.07K | 201.39K | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PMN Key Ratios
ProMIS Neurosciences, Inc. (PMN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -597.36% | -555.07% | -951.67% | - | -314.51% | -677.44% | -1815.54% | 27.46% | -521.61% | -237.99% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | - | 574.96% |
| Gross Margin | 100% | 100% | -393853.16% | -203296.1% | -71796.88% | - | - | - | - | - |
| Net Margin | -60838.5% | -2140431.58% | -615329.37% | -361814.19% | -118662.24% | - | - | - | - | - |
| Debt / Equity | - | - | - | - | 0.69x | - | - | - | - | 0.00x |
| Interest Coverage | -846.52x | - | - | - | -22.52x | -63.04x | -88.57x | 37.20x | - | - |
| FCF Conversion | 0.95x | 0.85x | 0.82x | 0.77x | 0.98x | 0.94x | 0.62x | -9.78x | 707.94x | 0.87x |
| Revenue Growth | 293.03% | -95.57% | 244.67% | 30.2% | 420.04% | -100% | - | - | - | - |
Related:PMN Dividend History·PMN Revenue History·PMN Price History·PMN P/E History·PMN Financial Ratios·PMN Institutional Holders
PMN SEC Filings & Documents
ProMIS Neurosciences, Inc. (PMN) SEC filings — annual & quarterly reports (10-K, 10-Q)
PMN Frequently Asked Questions
ProMIS Neurosciences, Inc. (PMN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ProMIS Neurosciences, Inc. (PMN) grew revenue by 0.0% over the past year. Growth has been modest.
ProMIS Neurosciences, Inc. (PMN) reported a net loss of $40.6M for fiscal year 2025.
Dividend & Returns
ProMIS Neurosciences, Inc. (PMN) has a return on equity (ROE) of -521.6%. Negative ROE indicates the company is unprofitable.
ProMIS Neurosciences, Inc. (PMN) had negative free cash flow of $35.5M in fiscal year 2025, likely due to heavy capital investments.